In a March 15 letter posted to the Food and Drug Administration’s Web site this week, AstraZeneca PLC (AZN) said it would stop selling tamoxifen, which it markets under the brand name Nolvadex, by the end of June.
In a March 15 letter posted to the Food and Drug Administration’s Web site this week, AstraZeneca PLC (AZN) said it would stop selling tamoxifen, which it markets under the brand name Nolvadex, by the end of June.
